Oncotelic Therapeutics, Inc.: 10-Q filed 2025-11-17
What Oncotelic Therapeutics, Inc. reported in its quarterly report filed 2025-11-17 (fiscal Q3 2025): 24 published measures, 74 facts as tagged in accession 0001493152-25-023834.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2025-11-17
- Fiscal period
- fiscal Q3 2025
- Accession
- 0001493152-25-023834 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Oncotelic Therapeutics, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 28,156,163 | USD | |
| At 2024-12-31 | 26,677,426 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 20,079,663 | USD | |
| At 2024-12-31 | 19,199,914 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 9,050,578 | USD | |
| At 2024-12-31 | 8,251,631 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 409,000 | USD | |
| At 2024-12-31 | 86,128 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | -1,047,365 | USD | 92 |
| 2025-01-01 to 2025-09-30 | -1,068,225 | USD | 273 |
| 2024-07-01 to 2024-09-30 | -3,304,486 | USD | 92 |
| 2024-01-01 to 2024-09-30 | -3,922,998 | USD | 274 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | -600,128 | USD | 273 |
| 2024-01-01 to 2024-09-30 | -636,387 | USD | 274 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | 923,000 | USD | 273 |
| 2024-01-01 to 2024-09-30 | 615,000 | USD | 274 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | -39,108,893 | USD | |
| At 2024-12-31 | -38,040,668 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 426,435,213 | shares | 92 |
| 2025-01-01 to 2025-09-30 | 414,315,703 | shares | 273 |
| 2024-07-01 to 2024-09-30 | 407,289,888 | shares | 92 |
| 2024-01-01 to 2024-09-30 | 403,428,494 | shares | 274 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 0 | USD/shares | 92 |
| 2025-01-01 to 2025-09-30 | 0 | USD/shares | 273 |
| 2024-07-01 to 2024-09-30 | -0.01 | USD/shares | 92 |
| 2024-01-01 to 2024-09-30 | 0 | USD/shares | 274 |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | 183,742 | USD | 273 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | -490,973 | USD | 92 |
| 2025-01-01 to 2025-09-30 | -658,039 | USD | 273 |
| 2024-07-01 to 2024-09-30 | -3,280,757 | USD | 92 |
| 2024-01-01 to 2024-09-30 | -3,544,559 | USD | 274 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 1,612,948 | USD | |
| At 2024-12-31 | 134,211 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 20,079,663 | USD | |
| At 2024-12-31 | 19,199,914 | USD |
Goodwill carrying amount
Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 2,788,230 | USD | |
| At 2024-12-31 | 2,788,230 | USD | |
| At 2023-12-31 | 5,988,230 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 3,976 | USD | |
| At 2024-12-31 | 18,976 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 490,973 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 658,039 | USD | 273 |
| 2024-07-01 to 2024-09-30 | 3,280,757 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 3,544,559 | USD | 274 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 439,446,318 | shares | |
| At 2024-12-31 | 407,289,618 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 43,765,008 | USD | |
| At 2024-12-31 | 42,219,400 | USD |
Total equity including noncontrolling interests
Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 8,076,500 | USD | |
| At 2025-06-30 | 7,393,895 | USD | |
| At 2025-03-31 | 7,183,446 | USD | |
| At 2024-12-31 | 7,477,512 | USD | |
| At 2024-09-30 | 8,131,972 | USD | |
| At 2024-06-30 | 11,503,623 | USD | |
| At 2024-03-31 | 11,249,391 | USD | |
| At 2023-12-31 | 11,611,537 | USD |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | -1,114,369 | USD | 92 |
| 2025-01-01 to 2025-09-30 | -1,268,184 | USD | 273 |
| 2025-04-01 to 2025-06-30 | 210,449 | USD | 91 |
| 2025-01-01 to 2025-03-31 | -364,264 | USD | 90 |
| 2024-07-01 to 2024-09-30 | -3,371,651 | USD | 92 |
| 2024-01-01 to 2024-09-30 | -4,124,998 | USD | 274 |
| 2024-04-01 to 2024-06-30 | -278,173 | USD | 91 |
| 2024-01-01 to 2024-03-31 | -475,175 | USD | 91 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 490,547 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 657,019 | USD | 273 |
| 2024-07-01 to 2024-09-30 | 80,277 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 343,347 | USD | 274 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | -623,396 | USD | 92 |
| 2025-01-01 to 2025-09-30 | -610,145 | USD | 273 |
| 2024-07-01 to 2024-09-30 | -90,894 | USD | 92 |
| 2024-01-01 to 2024-09-30 | -580,439 | USD | 274 |
Interest paid, net
Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | 285,260 | USD | 273 |
| 2024-01-01 to 2024-09-30 | 281,260 | USD | 274 |
Inspect the source
- Entity
- Oncotelic Therapeutics, Inc. / CIK 0000908259
- Captured
- 2026-09-20T05:05:47.535Z
- SEC response SHA-256
6c0026f9e455c874f284117994b59a028bad3a82bccf268424724837d8c3b9db
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000908259.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))